<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Permanent cardiac pacing: Overview of devices and indications</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Permanent cardiac pacing: Overview of devices and indications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Permanent cardiac pacing: Overview of devices and indications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H218864538"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiac pacemakers are effective treatments for a variety of bradyarrhythmias. By providing an appropriate heart rate and heart rate response, cardiac pacing can reestablish effective circulation and normalize hemodynamics that are compromised by a slow heart rate.</p><p>This topic will present a broad review of the role of cardiac pacing in a variety of settings. The management of the specific disorders is discussed separately as is a description of the different types of pacemakers and pacing modes. (See  <a class="medical medical_review" href="/z/d/html/1072.html" rel="external">"Sinus node dysfunction: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/910.html" rel="external">"Second-degree atrioventricular block: Mobitz type II"</a> and  <a class="medical medical_review" href="/z/d/html/950.html" rel="external">"Modes of cardiac pacing: Nomenclature and selection"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>Despite the myriad of clinical situations in which permanent pacing is considered, most management decisions regarding permanent pacemaker implantation are driven by the following clinical factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The association of symptoms with a bradyarrhythmia</p><p class="bulletIndent1"><span class="glyph">●</span>The location of the conduction abnormality</p><p class="bulletIndent1"><span class="glyph">●</span>The absence of a reversible cause</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Patients are often evaluated for permanent cardiac pacemaker placement because of symptoms that may be due to bradyarrhythmias (eg, dizziness, lightheadedness, syncope, fatigue, and poor exercise tolerance). These patients will often have evidence of persistent or intermittent sinus node dysfunction or atrioventricular (AV) conduction abnormalities.</p><p>Establishing a direct correlation between symptoms and bradyarrhythmias, typically by taking a careful history and documenting the cardiac rhythm with either an electrocardiogram or ambulatory monitoring (external or insertable cardiac monitor [also sometimes referred to as an implantable cardiac monitor or an implantable loop recorder]), is essential for choosing the optimal candidates for pacemaker insertion [<a href="#rid1">1,2</a>]. A direct correlation between symptoms and bradyarrhythmias will increase the likelihood of pacemaker therapy resulting in clinical improvement. Conversely, failure to document such a correlation, or the presence of an alternative explanation for symptoms, decreases the likelihood of benefit from pacemaker insertion.</p><p class="headingAnchor" id="H4"><span class="h2">Location of conduction abnormality</span><span class="headingEndMark"> — </span>The location of an AV conduction abnormality (ie, within the AV node or below the AV node in the His-Purkinje system) is an important determinant of both the probability and the likely pace of progression of conduction system disease  (<a class="graphic graphic_figure graphicRef63340" href="/z/d/graphic/63340.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/909.html" rel="external">"Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"</a> and  <a class="medical medical_review" href="/z/d/html/910.html" rel="external">"Second-degree atrioventricular block: Mobitz type II"</a>.)</p><p>Disease within the AV node is suggested by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>First-degree AV block with significant PR prolongation (see  <a class="medical medical_review" href="/z/d/html/913.html" rel="external">"First-degree atrioventricular block"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Second-degree AV block, Mobitz type I (Wenckebach) (see  <a class="medical medical_review" href="/z/d/html/909.html" rel="external">"Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal QRS complex</p><p></p><p>Disease below the AV node, in the His-Purkinje system, is suggested by:</p><p class="bulletIndent1"><span class="glyph">●</span>Normal or minimally prolonged PR interval</p><p class="bulletIndent1"><span class="glyph">●</span>Second-degree AV block, Mobitz type II (see  <a class="medical medical_review" href="/z/d/html/910.html" rel="external">"Second-degree atrioventricular block: Mobitz type II"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Third-degree (complete) AV block (see  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>A wide QRS complex (bundle branch block and/or fascicular block)</p><p></p><p>Disease in the His-Purkinje system is generally considered to be more concerning because it can progress quickly and lead to complete heart block. As a result, permanent pacemaker placement is likely to be recommended, as it is more likely to provide significant clinical benefit in such patients.</p><p class="headingAnchor" id="H130205457"><span class="h2">Reversible causes</span><span class="headingEndMark"> — </span>In addition to intrinsic conduction system disease, there are a number of extrinsic causes of bradyarrhythmias which are reversible. While patients who have a reversible bradyarrhythmia may require temporary pacemaker support, in most circumstances permanent cardiac pacing is not indicated or required. Some of the more common reversible causes of bradyarrhythmia include:</p><p class="bulletIndent1"><span class="glyph">●</span>Medications (eg, beta blockers, nondihydropyridine calcium channel blockers, antiarrhythmic medications [eg, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>]). (See  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block", section on 'Medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxic, metabolic, and electrolyte disturbances (eg, hyperkalemia, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute myocardial ischemia or infarction. (See <a class="local">'Post-myocardial infarction'</a> below and  <a class="medical medical_review" href="/z/d/html/45.html" rel="external">"Conduction abnormalities after myocardial infarction", section on 'Management of patients with AV block'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac trauma (eg, postoperative, blunt chest trauma, indwelling pulmonary artery catheters).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lyme disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac surgery, especially valve disorder surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transcatheter aortic valve implantation.</p><p></p><p>Reversible causes of bradyarrhythmias and the management of reversible causes with temporary cardiac pacing are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">"Temporary cardiac pacing", section on 'Reversible conditions'</a>.)</p><p class="headingAnchor" id="H463843599"><span class="h2">Concurrent ICD</span><span class="headingEndMark"> — </span>Some patients with an indication for a permanent pacemaker require an upgrade to an implantable cardioverter-defibrillator (ICD) or may require cardiac resynchronization therapy. ICDs (with the exception of the subcutaneous ICD) have antitachycardia and antibradycardia pacing therapeutic capabilities. In patients who have a permanent pacemaker and require an ICD or cardiac resynchronization therapy, the pacemaker should be upgraded to the appropriate device so that all functions can be served by one pulse generator. (See  <a class="medical medical_review" href="/z/d/html/97158.html" rel="external">"Subcutaneous implantable cardioverter defibrillators"</a>.)</p><p class="headingAnchor" id="H403204731"><span class="h1">TYPES OF PERMANENT PACEMAKER SYSTEMS</span><span class="headingEndMark"> — </span>Cardiac pacemakers generally consist of two components: a pulse generator  (<a class="graphic graphic_picture graphicRef104720" href="/z/d/graphic/104720.html" rel="external">picture 1</a>), which provides the electrical impulse for myocardial stimulation; and one or more electrodes (commonly referred to as leads), which deliver the electrical impulse from the pulse generator to the myocardium. A "leadless" pacemaker is now also available  (<a class="graphic graphic_picture graphicRef130297" href="/z/d/graphic/130297.html" rel="external">picture 2</a>). Transvenous leads have potential long-term complications (eg, venous thrombosis, infection, lead malfunction, etc). Leadless cardiac pacing systems offer the promise of long-term pacing capability without lead-associated complications.</p><p class="headingAnchor" id="H403204765"><span class="h2">Pulse generators</span><span class="headingEndMark"> — </span>Pulse generators are the "battery" component of the pacemaker  (<a class="graphic graphic_picture graphicRef104720" href="/z/d/graphic/104720.html" rel="external">picture 1</a>), generating the electrical impulse which is transmitted to the myocardium, resulting in the heart beat. Pulse generators are currently implanted most commonly in the infraclavicular region of the anterior chest wall. The majority are placed in a pre-pectoral position, but in some cases a sub-pectoral position is advantageous. The pulse generator transmits the electrical impulse to the myocardium via transvenous leads.</p><p>Epicardial systems are still available and may be necessary as a result of anatomical limitations to placing a transvenous lead(s). But these epicardial leads typically do not last as long.</p><p>For the leadless systems, the pulse generator and the electrode are one self-contained unit, which is positioned via the femoral vein into the right ventricle (RV). (See <a class="local">'Leadless systems'</a> below.)</p><p class="headingAnchor" id="H403204738"><span class="h2">Transvenous systems</span><span class="headingEndMark"> — </span>The vast majority of contemporary cardiac pacing systems utilize transvenous electrodes (leads) for transmission of the pacing impulses from the pulse generator to the myocardium. Transvenous leads, however, are associated with a nontrivial rate of long-term complications, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection</p><p class="bulletIndent1"><span class="glyph">●</span>Venous thrombosis and resultant subclavian vein occlusion</p><p class="bulletIndent1"><span class="glyph">●</span>Lead malfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid valve injury (resulting in tricuspid regurgitation)</p><p></p><p>The approach to the management of long-term transvenous lead complications is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108919.html" rel="external">"Cardiac implantable electronic devices: Periprocedural complications"</a> and  <a class="medical medical_review" href="/z/d/html/989.html" rel="external">"Cardiac implantable electronic devices: Long-term complications"</a> and  <a class="medical medical_review" href="/z/d/html/971.html" rel="external">"Cardiac implantable electronic device lead removal"</a>.)</p><p class="headingAnchor" id="H1917895571"><span class="h2">His bundle pacing</span><span class="headingEndMark"> — </span>His bundle pacing has been developed to prevent the harmful effects of RV pacing. In this modality, the RV lead is actively fixed in the area of the His bundle with subsequent ventricular activation via the His-Purkinje system. Theoretically, this will reduce the odds that dyssynchrony will occur. His bundle pacing may be beneficial in those with an anticipated high percent of RV pacing and possibly even those who have an indication for cardiac resynchronization therapy (CRT) such as a left bundle branch block. Clinical trials are ongoing [<a href="#rid3">3,4</a>].</p><p>While clinical trials are ongoing, registry data on His bundle pacing indicate a high rate of intervention for lead dislodgement. High capture thresholds result in more rapid battery depletion of the pacemaker pulse generator. This form of conduction system pacing is less commonly used than pacing in the region of the left bundle, as described below. (See <a class="local">'Left bundle pacing'</a> below.)</p><p class="headingAnchor" id="H1861008811"><span class="h2">Left bundle pacing</span><span class="headingEndMark"> — </span>Left bundle pacing has emerged as a competitor to His bundle pacing. While His bundle pacing typically occurs with the lead placed at the junction of the AV node and His bundle, left bundle pacing occurs with placement of the lead in the septum of the RV. Observational data show lower capture thresholds and dislodgement rates with left bundle area pacing compared with His bundle pacing. However, there are no large-scale randomized controlled trials.</p><p class="headingAnchor" id="H403204745"><span class="h2">Epicardial systems</span><span class="headingEndMark"> — </span>Epicardial cardiac pacemaker systems utilize a pulse generator with leads that are surgically attached directly to the epicardial surface of the heart. These systems have largely been replaced by transvenous systems for patients requiring long-term cardiac pacing, although there is still a role for the occasional patient with vascular access problems (eg, venous thrombosis, congenital anatomical variations, prosthetic tricuspid valve). The major role for epicardial pacing systems in current practice is for temporary pacing following cardiac surgery; such systems, however, are designed as temporary systems that must be removed within the first days to weeks following cardiac surgery.</p><p class="headingAnchor" id="H403204752"><span class="h2">Leadless systems</span><span class="headingEndMark"> — </span>In response to the limitations of both transvenous and epicardial pacing systems, efforts have been made to develop leadless cardiac pacing systems [<a href="#rid5">5-12</a>]. </p><p class="headingAnchor" id="H2542553142"><span class="h3">Leadless ventricular pacing</span><span class="headingEndMark"> — </span>Contemporary leadless systems include the pulse generator and the electrode within a single unit that is placed into the RV via a transvenous approach [<a href="#rid13">13</a>]. Multiple prospective, nonrandomized, multicenter trials with single-chamber RV leadless pacemakers followed for up to 12 months have demonstrated safety and efficacy [<a href="#rid6">6,9,11,14-17</a>].</p><p>In the SELECT-LV study, a prospective, nonrandomized study of safety and efficacy of leadless pacing for CRT among patients who "failed" conventional CRT, the leadless device was successfully implanted in 34 of 35 patients [<a href="#rid12">12</a>]. The primary efficacy endpoint (biventricular pacing on ECG at one month) was achieved in 33 of 34 patients; however, significant procedure and device-related complication occurred in three patients (9 percent) at the time of implant and in eight patients (23 percent) within the first month postimplant.</p><p>Leadless cardiac pacing systems have been approved for use in Europe since 2013, and, in April 2016, the first leadless cardiac pacing system was approved for use in the United States [<a href="#rid18">18</a>]. As of December 2016, two leadless pacemaker systems are approved by the US Food and Drug Administration (FDA) and commercially available, with slightly different sizes and implantation requirements [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Micra measures 2.6 x 0.7 cm, requires a 23-French introducer sheath, and was approved by the US FDA in 2016.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nanostim measures 4.2 x 0.6 cm and requires an 18-French sheath. However, the Nanostim was pulled from the market in 2017 because of early battery depletion issues. In 2022, the Aveir (a modification of the Nanostim device) was approved by the US FDA.</p><p></p><p>In general, leadless pacemakers have been placed via the transfemoral approach, but in select patients the leadless pacemaker has been successfully implanted via a transjugular approach [<a href="#rid20">20</a>].</p><p>Following device approval and introduction into general clinical practice, patients have been prospectively enrolled in a registry to allow for postmarketing "real world" evaluation of safety and efficacy [<a href="#rid6">6,7,9,21-29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Among a cohort of 1817 patients from the postapproval registry, 1801 (99.1 percent) had successful implantation of the Micra leadless pacemaker at 179 centers [<a href="#rid21">21</a>]. A total of 41 major complications were reported at 30-day follow-up (2.3 percent), comparable to the major complication rate in the pre-approval investigational trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 16 patients from three leadless pacemaker trials [<a href="#rid6">6,7,9</a>] who subsequently required device removal, the device was successfully extracted in 15 of 16 patients (94 percent), including all five patients in whom the device was in place for &lt;6 weeks [<a href="#rid22">22</a>]. In a subsequent report on the extraction experience among 1423 worldwide recipients of the Nanostim device, among whom 73 patients underwent attempted device retrieval (implant duration ranging from one day to four years), 66 devices (90 percent) were successfully retrieved [<a href="#rid23">23</a>]. Of the 73 attempted retrievals, 53 were done in response to the clinical alert about potential battery malfunction, with the other 20 patients (1.4 percent) having another clinical indication for device retrieval. This rate of necessary revision is similar to the reported experience with the Micra device, in which an actuarial revision rate of 1.4 percent has also been reported [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report has been published describing the successful removal of the Nanostim device up to nearly three years postimplant [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leadless pacemakers have been successfully implanted, with good short-term results, in patients at high risk of device infection, including hemodialysis patients (197 of 201 patients successfully implanted with no infections over mean 6.2 month follow-up) [<a href="#rid26">26</a>] and patients with a prior cardiac implantable electronic device (CIED) infection (105 patients implanted ≤30 days from prior infected CIED explant with no infections over mean 8.5 month follow-up) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among a small cohort of 43 patients who had the device implanted while on anticoagulant therapy, only one patient experienced a bleeding complication [<a href="#rid28">28</a>]. While implantation appears safe in patients treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or another oral anticoagulant, additional data are required to guide the optimal approach to implantation in this setting.</p><p></p><p>Leadless cardiac pacing holds promise as a long-term permanent cardiac pacing option for patients requiring single ventricle (RV only) pacing and appears both safe and efficacious in the short term.</p><p class="headingAnchor" id="H3903231954"><span class="h3">Leadless AV sequential pacing</span><span class="headingEndMark"> — </span>While initial leadless pacemakers could only sense and pace the RV, contemporary devices have the capacity to maintain AV synchrony:</p><p class="bulletIndent1"><span class="glyph">●</span>The US FDA-approved Micra AV uses an accelerometer-based algorithm to sense atrial activity and pace the ventricle and thus provide VDD pacing [<a href="#rid30">30</a>]. The device is used to treat patients with normal sinus function and complete AV block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The investigational leadless pacing system (Aveir DR) is composed of one device implanted in the right atrium and one device implanted in the RV. A prospective multicenter study of this system enrolled 190 patients with sinus node dysfunction and 100 with AV block [<a href="#rid31">31</a>]. The implantation procedure was successful in 98.3 percent of patients. The primary safety endpoint of freedom from complications at 90 days was met in 90.3 percent of patients. The first primary performance endpoint of adequate atrial capture threshold and sensing amplitude was met in 90.2 percent of patients. The second primary performance endpoint of at least 70 percent AV synchrony at three months while sitting was met in 97.3 percent of patients.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">COMMON INDICATIONS</span><span class="headingEndMark"> — </span>Permanent pacemaker implantation is most commonly indicated for sinus node dysfunction or high-grade/symptomatic AV block. Guidelines for implantation of cardiac pacemakers have been published jointly by the American College of Cardiology, the American Heart Association, and the Heart Rhythm Society (ACC/AHA/HRS) [<a href="#rid1">1</a>]. Although there are occasional cases that cannot be categorized according to these guidelines, they are, for the most part, comprehensive and have been widely endorsed. Similar guidelines have been established by the European Society of Cardiology [<a href="#rid2">2</a>].</p><p>Some indications for permanent pacing are relatively certain or unambiguous, while others require considerable expertise and judgment. It is helpful to divide the indications for pacemaker implantation into three specific categories, or classes, as defined by the ACC/AHA/HRS guidelines [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class I</strong> – Conditions in which permanent pacing is definitely beneficial, useful, and effective. In such conditions, implantation of a cardiac pacemaker is considered acceptable and necessary, provided that the condition is not due to a transient cause.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class II</strong> – Conditions in which permanent pacing may be indicated but there is conflicting evidence and/or divergence of opinion; class IIA refers to conditions in which the weight of evidence/opinion is in favor of usefulness/efficacy, while class IIb refers to conditions in which the usefulness/efficacy is less well established by evidence/opinion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class III</strong> – Conditions in which permanent pacing is not useful/effective and in some cases may be harmful.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Sinus node dysfunction</span><span class="headingEndMark"> — </span>The need for permanent pacing in patients with sinus node dysfunction is based largely upon the correlation of bradycardia with symptoms  (<a class="graphic graphic_table graphicRef70519" href="/z/d/graphic/70519.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]. While patients with a heart rate of less than 40 beats per minute or pauses of greater than four seconds are more likely to develop symptoms, there is no definitive threshold for heart rate (or pause length) that determines the absolute need for a permanent pacemaker. This is especially true if the bradycardia occurs during sleep.</p><p class="headingAnchor" id="H268605375"><span class="h3">Class I</span><span class="headingEndMark"> — </span>The following conditions are considered class I indications for pacemaker placement [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia in which symptoms are clearly related to the bradycardia (usually in patients with a heart rate below 40 beats per minute or frequent sinus pauses).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic chronotropic incompetence (an impaired heart rate response to exercise, generally defined as failure to achieve 85 percent of the age-predicted maximum heart rate during a formal or informal stress test or the inability to mount an age-appropriate heart rate during activities of daily living, [ie, as documented by ambulatory monitoring]). (See  <a class="medical medical_review" href="/z/d/html/1548.html" rel="external">"Prognostic features of stress testing in patients with known or suspected coronary disease", section on 'Heart rate response to exercise'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic sinus bradycardia due to the effects of clinically necessary evidence-based therapy (eg, antianginal or antiarrhythmic medications) with no effective alternative.</p><p></p><p class="headingAnchor" id="H268605381"><span class="h3">Class II</span><span class="headingEndMark"> — </span>The following are considered to be class II indications for pacemaker placement in patients with sinus node dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia (heart rate &lt;40 beats per minute) in a patient with symptoms suggestive of bradycardia, but without a clearly demonstrated association between bradycardia and symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinus node dysfunction in a patient with unexplained syncope.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic heart rates &lt;40 beats per minute while awake in a minimally symptomatic patient.</p><p></p><p class="bulletIndent1">Patients with sinus bradycardia of lesser severity (heart rate &gt;40 beats per minute) who complain of dizziness or other symptoms that correlate with the slower rates are also potential candidates for pacemaker therapy.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Acquired AV block</span><span class="headingEndMark"> — </span>Acquired AV block is the second most common indication for permanent pacemaker placement. Many disorders can cause acquired AV block, and these are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/910.html" rel="external">"Second-degree atrioventricular block: Mobitz type II"</a> and  <a class="medical medical_review" href="/z/d/html/909.html" rel="external">"Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"</a>.)</p><p class="headingAnchor" id="H268605399"><span class="h3">Class I</span><span class="headingEndMark"> — </span>The following conditions represent severe conduction disease and are generally considered to be class I indications for pacing when not attributable to reversible causes:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete (third-degree) AV block with or without symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced second-degree AV block (block of two or more consecutive P waves)</p><p class="bulletIndent1"><span class="glyph">●</span>Second-degree AV block, Mobitz type II (with or without symptoms)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic second-degree AV block, Mobitz type I (Wenckebach)</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise-induced second- or third-degree AV block (in the absence of myocardial ischemia)</p><p></p><p>Some controversy exists concerning asymptomatic patients with congenital complete heart block (eg, complete heart block and a structurally normal heart). The ACC/AHA/HRS guidelines recommend permanent pacemaker implantation in patients with congenital complete heart block and any high-risk feature (symptoms attributed to bradycardia, wide QRS rhythm, mean daytime heart rate &lt;50 beats per minute, complex ventricular ectopy, or ventricular dysfunction), while noting that permanent pacing is reasonable in individuals with congenital complete heart block without these risk factors [<a href="#rid1">1</a>]. Similar recommendations are included in the European guidelines [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H268605405"><span class="h3">Class II</span><span class="headingEndMark"> — </span>Patients with varying degrees of acquired AV block may still benefit from pacemaker placement. In such patients, determinations are often based upon correlation of bradycardia with symptoms, exclusion of other causes of symptoms, and in rare instances based on results of electrophysiology (EP) testing.</p><p>Conditions in which pacemaker placement can be considered include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>First-degree AV block when there is hemodynamic compromise because of effective AV dissociation secondary to a very long PR interval. (See  <a class="medical medical_review" href="/z/d/html/913.html" rel="external">"First-degree atrioventricular block", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bifascicular or trifascicular block associated with syncope that can be attributed to transient complete heart block, based upon the exclusion of other plausible causes of syncope  (<a class="graphic graphic_table graphicRef80379" href="/z/d/graphic/80379.html" rel="external">table 2</a>). Alternating bundle-branch block would also fulfill this criterion. (See  <a class="medical medical_review" href="/z/d/html/1063.html" rel="external">"Chronic bifascicular blocks"</a>.)</p><p></p><p>AV block in some patients may be due to the effects of medications (eg, antianginal or antiarrhythmic medications), a potentially reversible cause. However, if the pertinent medications cannot be discontinued (ie, alternative therapies are unavailable), permanent pacemaker insertion may be performed to allow for ongoing therapy with the drugs causing AV block [<a href="#rid1">1,32</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Post-myocardial infarction</span><span class="headingEndMark"> — </span>The indications for permanent pacing, including those related to patients after an MI, are presented in detail separately. In general, our approach is in agreement with published professional society guidelines for implantation of a permanent cardiac pacemaker [<a href="#rid1">1,33</a>]. (See  <a class="medical medical_review" href="/z/d/html/45.html" rel="external">"Conduction abnormalities after myocardial infarction"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Neurally-mediated syncope</span><span class="headingEndMark"> — </span>Evaluation of the patient with syncope can be clinically challenging. Once a diagnosis of neurocardiogenic syncope is established or suspected, effective treatment can be similarly challenging.</p><p>The use of pacemakers in this disorder is limited to very selected patients whose syncopal events are clearly associated with a marked cardioinhibitory or bradycardic event. Pacemaker treatment is effective only in patients with a marked isolated cardioinhibitory or bradycardic cause of syncope. However, since many patients have both bradycardic and vasodepressor components, some patients with an indication for pacemaker placement may not have a significant improvement in symptoms with pacing. In fact, pacing is rarely necessary in neutrally-mediated syncope. (See  <a class="medical medical_review" href="/z/d/html/111958.html" rel="external">"Reflex syncope in adults and adolescents: Treatment"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">OTHER INDICATIONS</span></p><p class="headingAnchor" id="H22"><span class="h2">Congenital complete heart block</span><span class="headingEndMark"> — </span>Congenital complete heart block has a variety of causes but most commonly is due to maternal neonatal lupus. Congenital complete heart block can present in utero, as a neonate, or later in childhood, with management directed by the time of presentation (ie, prenatal or postnatal) as well as the severity of symptoms. This topic is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Neuromuscular diseases</span><span class="headingEndMark"> — </span>A number of neuromuscular diseases are associated with AV block, including myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystrophy (limb-girdle), and peroneal muscular atrophy. Patients with these disorders have a class I indication for pacemaker placement once any evidence of second- or third-degree block develops. This is true even if the patient is asymptomatic, because there may be unpredictably rapid progression of AV conduction disease. (See  <a class="medical medical_review" href="/z/d/html/4912.html" rel="external">"Inherited syndromes associated with cardiac disease"</a>.)</p><p>Due to this potential for rapid progression, patients with these disorders are considered to have a class IIb indication for pacemaker placement even with first-degree AV block, regardless of symptoms [<a href="#rid1">1,34</a>]. Some of these patients may also require an implantable cardioverter-defibrillator or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.heart.org%2Fen%2Fhealth-topics%2Fheart-failure%2Ftreatment-options-for-heart-failure%2Fcardiac-resynchronization-therapy-crt&amp;token=yw8cv591Pn2%2BTNgphT%2BrKIusGIWm4tFUvil75U1MCFtjAN6wGGayZwh6Y1VCVI1YQSq3W4S3mF8z6JEQ6w6M9wIxTxZu3kyLMNMCICLSAlTNoY2df2VjIc1BOEc%2FlfDH0%2FqkmL2d5J4Bw8ntZKWigA%3D%3D&amp;TOPIC_ID=941" target="_blank">cardiac resynchronization therapy</a> (CRT) [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Long QT syndrome</span><span class="headingEndMark"> — </span>High-risk patients with congenital long QT syndrome have been treated with pacemakers to prevent ventricular arrhythmias, generally with a dual chamber pacemaker. However, most of these patients are now treated with an implantable cardioverter-defibrillator, which has pacing capability as well. (See  <a class="medical medical_review" href="/z/d/html/988.html" rel="external">"Congenital long QT syndrome: Treatment"</a>.)</p><p class="headingAnchor" id="H463843552"><span class="h3">Bradycardia-induced ventricular arrhythmias</span><span class="headingEndMark"> — </span>Bradycardia and/or prolonged pauses can precipitate ventricular arrhythmias. Although this phenomenon is most commonly associated with QT prolongation, it can occur in patients with a normal QT interval. Patients with pause-dependent ventricular arrhythmias, with or without QT prolongation, have an indication for pacemaker implantation. As noted above, however, many of these patients will be treated with an implantable cardioverter-defibrillator, which also has pacing capability. (See <a class="local">'Long QT syndrome'</a> above.)</p><p class="headingAnchor" id="H26"><span class="h2">Hypertrophic cardiomyopathy</span><span class="headingEndMark"> — </span>Pacing for medically refractory, symptomatic hypertrophic cardiomyopathy with significant resting or provoked left ventricular outflow obstruction is not generally recommended, particularly in patients who are candidates for septal reduction therapy [<a href="#rid36">36</a>]. The role of pacing in patients with HCM, along with the utilization of implantable cardioverter-defibrillators, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction", section on 'Therapies of limited benefit'</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Neither single-chamber RV pacing nor dual-chamber right heart pacing (RA and RV) are indicated for the treatment of heart failure symptoms in patients with heart failure. However, CRT, also referred to as biventricular pacing, is used to improve symptoms and survival in patients with medically refractory advanced heart failure, nonischemic or ischemic cardiomyopathy, and left bundle branch block. The use of CRT is discussed in detail separately, including the potential use of CRT in patients who have reduced left ventricular systolic function and an indication for permanent pacing in whom pacing will be frequent (ie, &gt;40 percent cumulative pacing). (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">CLASS III: PACING NOT INDICATED</span><span class="headingEndMark"> — </span>These are conditions that do not reliably improve with cardiac pacing, or are considered to lack adequate evidence of benefit from permanent pacing. Most of these conditions are bradyarrhythmias that are asymptomatic or due to reversible causes.</p><p class="bulletIndent1"><span class="glyph">●</span>Syncope of undetermined etiology. This may require extensive investigation, including ambulatory monitoring, neurologic evaluation, electrophysiologic testing, and perhaps tilt-table testing. Cardiac pacing may be considered if no other etiology of syncope is uncovered, and the history strongly suggests a cardiogenic origin. In such cases, the patient must understand that permanent pacing may not alleviate the symptoms, since no correlation between symptoms and rhythm has been documented. In addition, if a pacemaker is implanted because of a strong clinical suspicion that the patient's symptoms are due to a bradyarrhythmia, in the absence of any objective evidence of conduction system disease, reimbursement may be disallowed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia without significant symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinoatrial block or sinus arrest without significant symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic prolonged RR intervals with atrial fibrillation or other causes of transient ventricular pause.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic bradycardia during sleep.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic second-degree Mobitz I (Wenckebach) AV block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A hyperactive cardioinhibitory response to carotid sinus stimulation in the absence of symptoms or in the presence of vague symptoms such as dizziness, lightheadedness, or both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Right bundle branch block with left axis deviation without syncope or other symptoms compatible with intermittent AV block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversible AV block, such as those associated with electrolyte abnormalities, Lyme disease, sleep apnea, enhanced vagal tone, and some cases that occur postoperatively. AV block associated with drugs such as beta blockers, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, or <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> is not always reversible and can be associated with underlying conduction system disease [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block", section on 'Medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long QT syndrome or torsades de pointes due to reversible causes.</p><p></p><p class="headingAnchor" id="H2361396485"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a>.)</p><p class="headingAnchor" id="H1836561"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15666.html" rel="external">"Patient education: Pacemakers (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16936.html" rel="external">"Patient education: Bradycardia (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3448.html" rel="external">"Patient education: Pacemakers (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7839495"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General considerations</strong> – Two general factors guide the vast majority of decisions regarding permanent pacemaker insertion: the association of symptoms with an arrhythmia and the potential for progression of the rhythm disturbance, which is largely dependent on the anatomical location of the conduction abnormality. (See <a class="local">'General considerations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Association of symptoms with arrhythmia</strong> – Patients frequently present for consideration of pacemaker placement because of symptoms that may be due to bradyarrhythmias (eg, dizziness, lightheadedness, syncope, fatigue, and poor exercise tolerance). It is critical to attempt to establish a direct correlation between symptoms and bradyarrhythmias, which will increase the likelihood of recommending pacemaker placement. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk of progression</strong> – The location of an atrioventricular (AV) conduction abnormality (ie, within the AV node or below the AV node in the His-Purkinje system) is an important determinant of both the probability and the likely pace of progression of conduction system disease. Disease below the AV node, in the His-Purkinje system, is generally considered to be less stable; as a result, permanent pacemaker placement is more likely to be recommended. (See <a class="local">'Location of conduction abnormality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of pacemaker systems</strong> – Pacemakers  (<a class="graphic graphic_picture graphicRef104720" href="/z/d/graphic/104720.html" rel="external">picture 1</a>) are most commonly placed in a thoracic pre-pectoral position and connected to one or two transvenous leads, which are positioned endocardially. Epicardial lead placement is still a viable option for patients with limited transvenous access. Leadless pacing systems are now available and hold significant promise for the future. (See <a class="local">'Types of permanent pacemaker systems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for pacemaker implantation</strong> – The most common indications for pacemaker implantation are sinus node dysfunction followed by AV block. All other indications are much less common and include neurocardiogenic syncope and iatrogenic causes (eg, post-AV node ablation). While patients with a heart rate of less than 40 beats per minute, or pauses of greater than four seconds, are more likely to develop symptoms, there is no definitive threshold for heart rate (or pause length) which determines the absolute need for a permanent pacemaker. (See <a class="local">'Common indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to consider CRT or ICD</strong> – With the advent of cardiac resynchronization therapy (CRT), it is important to also take into consideration the patient's left ventricular function at the time a pacemaker is considered. If the patient has left ventricular dysfunction and requires frequent pacing, it would be appropriate to consider CRT and/or an implantable cardioverter-defibrillator. Whether His bundle or left bundle pacing will provide benefits similar to CRT is yet to be determined. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pacing not indicated</strong> – Conditions with a lack of adequate evidence of benefit from permanent pacing, in which permanent pacing is generally non indicated, include, among others, syncope of undetermined etiology, asymptomatic sinus bradycardia, asymptomatic first-degree and second-degree Mobitz I (Wenckebach) AV block, reversible AV block, and long QT syndrome or torsades de pointes due to a reversible cause. (See <a class="local">'Class III: Pacing not indicated'</a> above.)</p><p></p><p class="headingAnchor" id="H936260733"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David L Hayes, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74:e51.</a></li><li><a class="nounderline abstract_t">Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; 42:3427.</a></li><li><a class="nounderline abstract_t">Upadhyay GA, Vijayaraman P, Nayak HM, et al. On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial. Heart Rhythm 2019; 16:1797.</a></li><li><a class="nounderline abstract_t">Upadhyay GA, Vijayaraman P, Nayak HM, et al. His Corrective Pacing or Biventricular Pacing for Cardiac Resynchronization in Heart Failure. J Am Coll Cardiol 2019; 74:157.</a></li><li><a class="nounderline abstract_t">Auricchio A, Delnoy PP, Butter C, et al. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study. Europace 2014; 16:681.</a></li><li><a class="nounderline abstract_t">Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation 2014; 129:1466.</a></li><li><a class="nounderline abstract_t">Knops RE, Tjong FV, Neuzil P, et al. Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial. J Am Coll Cardiol 2015; 65:1497.</a></li><li><a class="nounderline abstract_t">Ritter P, Duray GZ, Steinwender C, et al. Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. Eur Heart J 2015; 36:2510.</a></li><li><a class="nounderline abstract_t">Reddy VY, Exner DV, Cantillon DJ, et al. Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker. N Engl J Med 2015; 373:1125.</a></li><li><a class="nounderline abstract_t">Miller MA, Neuzil P, Dukkipati SR, Reddy VY. Leadless Cardiac Pacemakers: Back to the Future. J Am Coll Cardiol 2015; 66:1179.</a></li><li><a class="nounderline abstract_t">Reynolds D, Duray GZ, Omar R, et al. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med 2016; 374:533.</a></li><li><a class="nounderline abstract_t">Reddy VY, Miller MA, Neuzil P, et al. Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing: The SELECT-LV Study. J Am Coll Cardiol 2017; 69:2119.</a></li><li><a class="nounderline abstract_t">Sperzel J, Burri H, Gras D, et al. State of the art of leadless pacing. Europace 2015; 17:1508.</a></li><li><a class="nounderline abstract_t">Tjong FVY, Knops RE, Neuzil P, et al. Midterm Safety and Performance of a Leadless Cardiac Pacemaker: 3-Year Follow-up to the LEADLESS Trial (Nanostim Safety and Performance Trial for a Leadless Cardiac Pacemaker System). Circulation 2018; 137:633.</a></li><li><a class="nounderline abstract_t">Sperzel J, Defaye P, Delnoy PP, et al. Primary safety results from the LEADLESS Observational Study. Europace 2018; 20:1491.</a></li><li><a class="nounderline abstract_t">Piccini JP, Stromberg K, Jackson KP, et al. Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: Results from the Micra Transcatheter Pacing System Global Clinical Trial. Heart Rhythm 2017; 14:685.</a></li><li><a class="nounderline abstract_t">Duray GZ, Ritter P, El-Chami M, et al. Long-term performance of a transcatheter pacing system: 12-Month results from the Micra Transcatheter Pacing Study. Heart Rhythm 2017; 14:702.</a></li><li class="breakAll">http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm494390.htm (Accessed on April 08, 2016).</li><li><a class="nounderline abstract_t">El-Chami MF, Merchant FM, Leon AR. Leadless Pacemakers. Am J Cardiol 2017; 119:145.</a></li><li><a class="nounderline abstract_t">Saleem-Talib S, van Driel VJ, Chaldoupi SM, et al. Leadless pacing: Going for the jugular. Pacing Clin Electrophysiol 2019; 42:395.</a></li><li><a class="nounderline abstract_t">El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm 2018; 15:1800.</a></li><li><a class="nounderline abstract_t">Reddy VY, Miller MA, Knops RE, et al. Retrieval of the Leadless Cardiac Pacemaker: A Multicenter Experience. Circ Arrhythm Electrophysiol 2016; 9.</a></li><li><a class="nounderline abstract_t">Lakkireddy D, Knops R, Atwater B, et al. A worldwide experience of the management of battery failures and chronic device retrieval of the Nanostim leadless pacemaker. Heart Rhythm 2017; 14:1756.</a></li><li><a class="nounderline abstract_t">Grubman E, Ritter P, Ellis CR, et al. To retrieve, or not to retrieve: System revisions with the Micra transcatheter pacemaker. Heart Rhythm 2017; 14:1801.</a></li><li><a class="nounderline abstract_t">González Villegas E, Al Razzo O, Silvestre García J, Mesa García J. Leadless pacemaker extraction from a single-center perspective. Pacing Clin Electrophysiol 2018; 41:101.</a></li><li><a class="nounderline abstract_t">El-Chami MF, Clementy N, Garweg C, et al. Leadless Pacemaker Implantation in Hemodialysis Patients: Experience With the Micra Transcatheter Pacemaker. JACC Clin Electrophysiol 2019; 5:162.</a></li><li><a class="nounderline abstract_t">El-Chami MF, Johansen JB, Zaidi A, et al. Leadless pacemaker implant in patients with pre-existing infections: Results from the Micra postapproval registry. J Cardiovasc Electrophysiol 2019; 30:569.</a></li><li><a class="nounderline abstract_t">San Antonio R, Chipa-Ccasani F, Apolo J, et al. Management of anticoagulation in patients undergoing leadless pacemaker implantation. Heart Rhythm 2019; 16:1849.</a></li><li><a class="nounderline abstract_t">Tachibana M, Banba K, Matsumoto K, Ohara M. The feasibility of leadless pacemaker implantation for superelderly patients. Pacing Clin Electrophysiol 2020; 43:374.</a></li><li><a class="nounderline abstract_t">Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker: Results From the MARVEL 2 Study. JACC Clin Electrophysiol 2020; 6:94.</a></li><li><a class="nounderline abstract_t">Knops RE, Reddy VY, Ip JE, et al. A Dual-Chamber Leadless Pacemaker. N Engl J Med 2023; 388:2360.</a></li><li><a class="nounderline abstract_t">Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 2004; 44:105.</a></li><li><a class="nounderline abstract_t">American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:e78.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.</a></li><li><a class="nounderline abstract_t">Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm 2012; 9:1890.</a></li><li><a class="nounderline abstract_t">Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142:e558.</a></li></ol></div><div id="topicVersionRevision">Topic 941 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30412709" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34455430" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31096064" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31078637" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : His Corrective Pacing or Biventricular Pacing for Cardiac Resynchronization in Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497573" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24664277" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Permanent leadless cardiac pacing: results of the LEADLESS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881930" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26045305" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321198" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337997" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Leadless Cardiac Pacemakers: Back to the Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26551877" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Leadless Intracardiac Transcatheter Pacing System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28449772" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing: The SELECT-LV Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26024918" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : State of the art of leadless pacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29431664" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Midterm Safety and Performance of a Leadless Cardiac Pacemaker: 3-Year Follow-up to the LEADLESS Trial (Nanostim Safety and Performance Trial for a Leadless Cardiac Pacemaker System).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29365073" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary safety results from the LEADLESS Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28111349" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: Results from the Micra Transcatheter Pacing System Global Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192207" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term performance of a transcatheter pacing system: 12-Month results from the Micra Transcatheter Pacing Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192207" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-term performance of a transcatheter pacing system: 12-Month results from the Micra Transcatheter Pacing Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27889044" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Leadless Pacemakers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30653690" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Leadless pacing: Going for the jugular.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30103071" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932427" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Retrieval of the Leadless Cardiac Pacemaker: A Multicenter Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705736" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A worldwide experience of the management of battery failures and chronic device retrieval of the Nanostim leadless pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28713024" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : To retrieve, or not to retrieve: System revisions with the Micra transcatheter pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29194683" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Leadless pacemaker extraction from a single-center perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784685" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Leadless Pacemaker Implantation in Hemodialysis Patients: Experience With the Micra Transcatheter Pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30661279" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Leadless pacemaker implant in patients with pre-existing infections: Results from the Micra postapproval registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31125672" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of anticoagulation in patients undergoing leadless pacemaker implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32134134" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The feasibility of leadless pacemaker implantation for superelderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31709982" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker: Results From the MARVEL 2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37212442" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Dual-Chamber Leadless Pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234417" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23256914" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760083" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Arrhythmias in the muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215931" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
